Yeung C K, Wong K L, Wong W S, Chan K H
J Rheumatol. 1986 Dec;13(6):1053-8.
Serum beta 2-microglobulin (beta 2-M) was measured in 115 patients with systemic lupus erythematosus (SLE) on 192 occasions. Raised beta 2-M was found in 16.4% of patients with only extrarenal manifestations of SLE, in 29.2% of patients with renal manifestation but an endogenous creatinine clearance greater than 80 ml/min/1.73 m2 and in 65.7% of patients with decreased creatinine clearance. beta 2-M was higher in SLE than non-SLE glomerulonephritides matched for creatinine clearance. Using an arbitrary scoring system, renal, extrarenal and serological activity correlated with beta 2-M. Changes in clinical activity on repeat studies were reflected by changes in beta 2-M. Serum beta 2-M can serve as a monitor of disease activity in SLE.
对115例系统性红斑狼疮（SLE）患者进行了192次血清β2-微球蛋白（β2-M）检测。仅出现SLE肾外表现的患者中，16.4%的患者β2-M升高；出现肾脏表现但内生肌酐清除率大于80 ml/min/1.73 m²的患者中，29.2%的患者β2-M升高；肌酐清除率降低的患者中，65.7%的患者β2-M升高。在肌酐清除率匹配的情况下，SLE患者的β2-M高于非SLE肾小球肾炎患者。采用一种任意评分系统，肾脏、肾外和血清学活动与β2-M相关。重复研究时临床活动的变化通过β2-M的变化得以体现。血清β2-M可作为SLE疾病活动的监测指标。
